$VRTX

Avaí Bio achieves critical Master Cell Bank milestone for α-Klotho protein therapy, partnering with Austrianova as cell therapy market surges toward $45B by 2035.

CRISPR Therapeutics stock declined 9% following a $585.2M convertible notes offering. The gene-editing company boasts FDA-approved Casgevy therapy and $1.8B in reserves but faces steep losses.

Eli Lilly dominates weight management, Vertex controls cystic fibrosis, and Pfizer offers undervalued shares with 6.3% dividend yield.

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.

UNCF New England Gala raises record $800,000 for historically Black colleges and universities, supporting scholarships and institutional sustainability.

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.

U.S. stocks gained Tuesday as crude crashed to $85/barrel on Trump's Iran conflict signals, with S&P 500 up 0.3% and VIX falling 9.3%.

$VERX surges 6.3% after kidney drug povetacicept achieves Phase 3 trial success with 52% proteinuria reduction, positioning FDA approval by year-end.

Regeneron and Vertex Pharmaceuticals emerge as compelling 2026 biotech investments, with REGN valued at 17x and VERX at 24x forward earnings, offering growth and stability respectively.

Vertex Pharmaceuticals offers profitable gene-editing exposure versus CRISPR's pipeline-dependent model. Casgevy's slow adoption and high costs make Vertex's diversified, profitable business more attractive for risk-averse investors despite lower upside potential.

Absci appoints Vertex Pharma veteran Dr. Ransi Somaratne as Chief Medical Officer to lead clinical development of AI-designed therapeutics, signaling execution focus.

CVS and Vertex poised for growth through 2026 via operational improvements and expanded product pipelines. Both companies expected to deliver significant shareholder value.

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.

Vertex Pharmaceuticals expands beyond cystic fibrosis dominance into gene-editing treatments for blood disorders and pain management, targeting $13.1B revenue with non-CF products generating $500M+.

Vertex Pharmaceuticals needs 26% annual growth to turn $100K into $1M by 2036, but its maturing cystic fibrosis franchise and competitive pressures make this ambitious target unlikely despite solid fundamentals.

CRISPR stock rallied 12% on pipeline momentum despite quarterly losses and minimal revenue, buoyed by cash reserves and CTX611 candidate progress.

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.

U.S. markets rally on softer inflation data boosting rate-cut expectations. Small-cap stocks, commodities, and growth sectors lead as investors bet on lower borrowing costs ahead.

CRISPR Therapeutics reports strong Q4 results with Casgevy gene therapy generating $116M revenue and 147 patient initiations, signaling accelerating adoption and market confidence.